Close Menu

NEW YORK (GenomeWeb) – Cowen, Leerink, and JP Morgan have initiated coverage of immunoassay firm Quanterix.

Cowen and Leerink both gave the company an Outperform rating with the former giving no price target and the latter a price target of $27. JP Morgan initiated coverage with an Overweight rating and a price target of $24.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Financial Times reports the US bolstering its ability to track SARS-CoV-2 alterations.

The New York Times reports that Cedars-Sinai researchers have uncovered a new strain of SARS-CoV-2 in Southern California.

In Nucleic Acids Research this week: pan-cancer atlas focus on miRNA biogenesis mutations, methylation analysis of pig skeletal muscles, and more.

President-elect Joe Biden has nominated Eric Lander to serve as director of the Office of Science and Technology Policy, the Associated Press says.

Feb
11
Sponsored by
Foundation Medicine

In this session, the first in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified biomarkers related to homologous recombination deficiency and DNA damage repair.

Feb
18
Sponsored by
BD

The composition of the immune infiltrate in the human tumor microenvironment is a critical determinant of disease progression. 

Feb
24
Sponsored by
SCHOTT MINIFAB

Developing a fully integrated consumable cartridge for an automated diagnostic platform is a significant challenge. More challenging still is developing such a cartridge in response to a deadly global virus pandemic amid market uncertainty and extraordinary time constraints. 

Feb
25
Sponsored by
Foundation Medicine

In this session, the second in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review cases in which patient genomic profiles exhibit common driver mutations in tumor types considered “off label” for targeted therapies associated with those mutations.